Ovarian cancer is a leading cause of gynecological cancer-related deaths in women worldwide. Due to the lack of specific signs and symptoms at the early stages of the disease, ovarian cancer is usually diagnosed late, and peritoneal and distant metastases are common at diagnosis. While there is no curative treatment for advanced ovarian cancer, our understanding of the disease has significantly advanced in the past decade. Ovarian cancer is a highly heterogeneous disease. A key feature of advanced ovarian cancer is malignant ascites, the pathological accumulation of fluid in the peritoneal cavity. Inflammation and inflammasomes play a key role in this process. In this book, an international team of researchers and clinicians provide an up-to-date information on aspects of heterogeneity, pathological mechanisms, and treatment strategies. The heterogeneity of ovarian cancers is covered in the chapter on subtypes of ovarian cancer. The pathological mechanisms with emphasis on malignant ascites and inflammasomes, and how they contribute to tumor progression and chemoresistance are comprehensively presented in three chapters. The last three chapters focus on current and future treatment strategies with emphasis on the real-life challenges faced in the clinics by gyneco-oncologists in daily practice in the management of recurrent high grade serous ovarian cancer, theranostics, and immunotherapy. The chapters of this book are topical. This book will be valuable to healthcare professionals caring for individuals with ovarian cancer and researchers involved in ovarian cancer.

Contents

• Foreword
• Preface
• List of Contributors
• 1. Rare Ovarian Tumors
  Aaron Varghese and Shashikant Lele.
  • INTRODUCTION
  • OVARIAN GERM CELL TUMORS
  • OVARIAN SEX CORD-STROMAL TUMORS
  • EPITHELIAL OVARIAN CARCINOMA
  • CLINICAL MANAGEMENT OF OVARIAN GERM CELL TUMORS
  • CLINICAL MANAGEMENT OF OVARIAN SEX CORD-STROMAL TUMORS
  • CLINICAL MANGEMENT OF EPITHELIAL OVARIAN CARCINOMA
  • CONCLUSION
  • REFERENCES
• 2. Chemoresistance in Ovarian Cancer: The Role of Malignant Ascites
  Mariana Nunes and Sara Ricardo.
  • INTRODUCTION
  • TRANSCOELOMIC DISSEMINATION
  • THE MICROENVIRONMENT OF MALIGNANT ASCITES
  • THE MANAGEMENT OF MALIGNANT ASCITES AND CHEMORESISTANCE
  • MALIGNANT ASCITES AS AN OPPORTUNITY FOR TRANSLATION RESEARCH
  • A PERSONALIZED MEDICINE APPROACH FOR OVARIAN CANCER USING MALIGNANT ASCITES
  • CONCLUSION
  • REFERENCES
• 3. Ovarian Cancer Ascites as a Liquid Tumor Microenvironment
  Diana Nunes and Sara Ricardo.
  • INTRODUCTION
  • CLASSIFICATION OF OVARIAN CANCER
  • MALIGNANT ASCITES AS A LIQUID TUMOR MICROENVIRONMENT
  • CONCLUSION
  • REFERENCES
• 4. The Role of Inflammasomes in Ovarian Cancer
  Bárbara da Silva Martins, Roberto Silva Ribeiro Junior, Tatiana Massariol Pimenta, Josiany Carlos de Souza, and Leticia Batista Azevedo Rangel.
  • INTRODUCTION
  • INFLAMMATION AND INFLAMMASOMES IN OVARIAN CANCER
  • GSDM
  • CONCLUSION
  • REFERENCES
• 5. Molecular Imaging and Theranostics in Ovarian Cancer: The Role of Nuclear Medicine
  Venesen Pillay, Bawinile Hadebe, and Mariza Vorster.
  • INTRODUCTION
  • RISK FACTORS
  • DIAGNOSIS
  • SCREENING AND PREVENTION
  • TREATMENT
  • RECURRENT DISEASE
  • MORPHOLOGICAL IMAGING OF OVARIAN CANCER
  • ¹⁸F-FDG PET/CT
  • THERANOSTICS IN OVARIAN CANCER
  • CONCLUSION
  • REFERENCES
• 6. Recurrent High Grade Serous Ovarian Cancer Management
  Mathieu Luyckx, Jean-Luc Squifflet, Annika M. Bruger, and Jean-François Baurain.
  • INTRODUCTION
  • TIME TO RECURRENCE
  • TREATMENT FOR RECURRENCE
  • PLATINUM-RESISTANT DISEASE
  • PLATINUM-SENSITIVE DISEASE
  • CONCLUSION
  • REFERENCES
• 7. The Use of Immunotherapy for Treatment of Gynecologic Malignancies
  Amma F. Agyemang and Shashikant Lele.
  • INTRODUCTION
  • OVARIAN CANCER
  • ENDOMETRIAL CANCER
  • CERVICAL CANCER
  • VULVAR CANCER
  • CONCLUSION
  • REFERENCES

Shashikant Lele, MD, FACOG, is a Professor of Oncology, Chief of Gynecologic Oncology, and Clinical Chair of the Division of Surgical Subspecialties at the Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. After completing MD degree at JJ Hospital-Grant Medical College, Mumbai, India, he undertook his Residency program at Mount Sinai Hospital, Cleveland, OH, USA. He is certified in Gynecologic Oncology and Obstetrics and Gynecology by the American Board of Obstetrics and Gynecology. His specialization is in cancers of the cervix, endometrium, ovary, uterus, vagina, and vulva with a special interest in Gynecologic Oncology group studies involving clinical and scientific research on ovarian cancer surgery and ovarian cancer chemotherapy. He has given many featured talks including “Women: Listen to Your Body”, an awareness video for women about gynecologic cancers to recognize warning signs so that preemptive approaches can be taken at any sign of irregularity. He has been involved in many clinical trials evaluating novel anticancer chemotherapy of gynecologic cancers. Professor Lele has extensively published in the field including articles in New England Journal of Medicine, Nature Genetics, JAMA Oncology and Journal of Gynecologic Oncology.

Ovarian Cancer

ISBN: 978-0-6453320-8-7

DOI: https://doi.org/10.36255/exon-publications-ovarian-cancer

Edited by

Shashikant Lele, MD, FACOG, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Published by

Exon Publications, Brisbane, Australia

Copyright© 2022 Exon Publications

Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). https://creativecommons.org/licenses/by-nc/4.0/. Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The book in its entirety is subject to copyright by the publisher. The reproduction, modification, replication and display of the book in its entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.

Notice to the user

The views and opinions expressed in this book are believed to be accurate at the time of publication. The publisher, editors or authors cannot be held responsible or liable for any errors, omissions or consequences arising from the use of the information contained in this book. The publisher makes no warranty, implicit or explicit, with respect to the contents of this book, or its use.

First Published in September 2022